A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer-Reference-Cited by-同舟云学术

A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer

Published:2005-06 Issue:16_suppl Volume:23 Page:3046-3046
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gomez H. L.¹,Chavez M. A.¹,Doval D. C.¹,Chow L. W. C.¹,Wood B. A.¹,Berger M. S.¹,Sledge G. W.¹

Affiliation:

1. Inst Especializado de Enfermedades Neoplasica, Lima, Peru; Hosp Alberto Sabogal, Lima, Peru; Rajiv Gandhi Cancer Institute and Research Ctr, New Delhi, India; Queen Mary Hosp, Hong Kong, Hong Kong Special Administrative Region of China; GlaxoSmithKline, Collegeville, PA; Indiana Univ, Indianapolis, IN

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.3046

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. β-Cyclodextrin anchored neem carbon dots for enhanced electrochemical sensing performance of an anticancer drug, lapatinib via host-guest inclusion;Journal of Molecular Liquids;2022-03

2. Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab;Japanese Journal of Clinical Oncology;2011-03-15

3. Lapatinib;Recent Results in Cancer Research;2009-10-07

4. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer;Nature Clinical Practice Oncology;2008-10-21

5. Lapatinib and Ixabepilone for the Treatment of Metastatic Breast Cancer;Pharmacotherapy;2008-10